MRNACongressional Stock Trades
Moderna, Inc. Common Stock
Biological Products, (No Diagnostic Substances)
Congressional stock trades in Moderna, Inc. Common Stock (MRNA) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
8
Politicians Trading
4
Last Traded
Sep 24, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Maria Elvira SalazarR | Oct 7, 2026 | Sep 24, 2026 | Sell | $1,001 - $15,000 | +13.35% |
| Maria Elvira SalazarR | Sep 9, 2026 | Aug 19, 2026 | Buy | $1,001 - $15,000 | +26.64% |
| Maria Elvira SalazarR | Sep 9, 2026 | Aug 19, 2026 | Sell | $1,001 - $15,000 | +26.64% |
| Ro KhannaD | Sep 4, 2026 | Aug 24, 2026 | Buy | $1,001 - $15,000 | +59.00% |
| Ro KhannaD | Sep 4, 2026 | Aug 3, 2026 | Sell | $1,001 - $15,000 | +300.49% |
| Robert BresnahanR | May 8, 2025 | Apr 8, 2025 | Sell | $1,001 - $15,000 | +796.23% |
| Robert BresnahanR | Mar 27, 2025 | Feb 25, 2025 | Buy | $1,001 - $15,000 | +563.55% |
| Julie JohnsonD | Feb 12, 2025 | Jan 15, 2025 | Sell | $1,001 - $15,000 | +535.12% |
Price History
About Moderna, Inc. Common Stock
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
4 members of Congress have disclosed 8 trades in Moderna, Inc. Common Stock (MRNA). Most active: Maria Elvira Salazar (3), Ro Khanna (2), Robert Bresnahan (2).
Across all disclosures, members of Congress reported 3 purchases and 5 sales of Moderna, Inc. Common Stock (MRNA). The most recent trade was on Sep 24, 2026.
Ro Khanna disclosed buying Moderna, Inc. Common Stock (MRNA) on Aug 24, 2026, valued at $1,001 - $15,000.
Maria Elvira Salazar disclosed selling Moderna, Inc. Common Stock (MRNA) on Sep 24, 2026, valued at $1,001 - $15,000.
From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.